A consortium of investors including private equity firms Adage Capital Partners, Avidity Partners, Boxer Capital, Darwin Global Management, Deep Track Capital, Farallon Capital Management, Logos Capital, Perceptive Advisors and RTW Investments, completed a $180m investment in Spyre Therapeutics, a biotechnology company. Spyre Therapeutics intends to use the net proceeds from the PIPE financing, together with the Spyre's existing cash, cash equivalents, and marketable securities, to fund its pipeline programs, and for general corporate purposes and working capital. Spyre also expects that the net proceeds will extend its cash runway to fund its operating plan well into 2027.